Angiotensin II receptor blockade and insulin sensitivity in overweight and obese adults with elevated blood pressure

Therapeutic Advances in Cardiovascular Disease

Volumn 7, Issue 1, 2013, Pages 11-20

  Marinik, Elaina L ^a   Frisard, Madlyn I ^a   Hulver, Matthew W ^a   Rivero, Jose M ^a   Davy, Brenda M ^a   Savla, Jyoti S ^a   Davy, Kevin P ^a  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

Author keywords

hypertension; insulin sensitivity index; olmesartan; renin angiotensin system

Indexed keywords

ADIPONECTIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; INSULIN; INTERLEUKIN 10; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; OLMESARTAN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BODY FAT; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; FEMALE; GLUCOSE TOLERANCE; HUMAN; HUMAN TISSUE; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN RESPONSE; INSULIN SENSITIVITY; INTERVENTION STUDY; INTRAVENOUS GLUCOSE TOLERANCE TEST; LIPOPROTEIN BLOOD LEVEL; MALE; OBESITY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

ANGIOTENSIN RECEPTOR ANTAGONISTS; BIOPSY; CROSS-OVER STUDIES; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; HYPERTENSION; IMIDAZOLES; INSULIN RESISTANCE; MALE; MIDDLE AGED; MUSCLE, SKELETAL; OBESITY; OVERWEIGHT; RENIN-ANGIOTENSIN SYSTEM; TETRAZOLES; TREATMENT OUTCOME;

EID: 84873607082     PISSN: 17539447     EISSN: 17539455     Source Type: Journal    
DOI: 10.1177/1753944712471740     Document Type: Article

References (46)

1. Andraws R. Brown D. (2007) Effect of inhibition of the renin–angiotensin system on development of type 2 diabetes mellitus (meta-analysis of randomized trials). Am J Cardiol 99: 1006–1012.
2. Benndorf R. Rudolph T. Appel D. Schwedhelm E. Maas R. Schulze F. et al. (2006) Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism 55: 1159–1164.
3. Benson S. Pershadsingh H. Ho C. Chittiboyina A. Desai P. Pravenec M. et al. (2004) Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 43: 993–1002.
4. Berria R. Wang L. Richardson D. Finlayson J. Belfort R. Pratipanawatr T. et al. (2006) Increased collagen content in insulin-resistant skeletal muscle. Am J Physiol Endocrinol Metab 290: E560–E565.
5. Boston R. Stefanovski D. Moate P. Sumner A. Watanabe R. Bergman R. (2003) MINMOD millennium: a computer program to calculate glucose effectiveness and insulin sensitivity from the frequently sampled intravenous glucose tolerance test. Diabetes Technol Ther 5: 1003–1015.
6. Chan J. Rimm E. Colditz G. Stampfer M. Willett W. (1994) Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 17: 961–969.
7. Defronzo R. Ferrannini E. (1991) Insulin resistance a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14: 173–194.
8. de Luis D. Conde R. Gonzalez-Sagrado M. Aller R. Izaola O. Duenas A. et al. (2010) Effects of telmisartan vs olmesartan on metabolic parameters, insulin resistance and adipocytokines in hypertensive obese patients. Nutr Hosp 25: 275–279.
9. Derosa G. Maffioli P. Ferrari I. Palumbo I. Randazzo S. Fogari E. et al. (2011) Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients. Hypertens Res 34: 145–151.
10. Elliott W. Meyer P. (2007) Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet 369: 201–207.
11. Erbe D. Gartrell K. Zhang Y. Suri V. Kirincich S. Will S. et al. (2006) Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascul Pharmacol 45: 154–162.
12. Ferrannini E. Simonson D. Katz L. Reichard G. Jr Bevilacqua S. Barrett E. et al. (1988) The disposal of an oral glucose load in patients with non-insulin-dependent diabetes. Metabolism 37: 79–85.
13. Fogari R. Derosa G. Zoppi A. Rinaldi A. Lazzari P. Fogari E. et al. (2005) Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients. Hypertens Res 28: 209–214.
14. Fogari R. Zoppi A. Corradi L. Lazzari P. Mugellini A. Lusardi P. (1998) Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients. Br J Clin Pharmacol 46: 467–471.
15. Fogari R. Zoppi A. Ferrari I. Mugellini A. Preti P. Lazzari P. et al. (2009) Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients. Horm Metab Res 41: 893–898.
16. Frisard M. McMillan R. Marchand J. Wahlberg K. Wu Y. Voelker K. et al. (2010) Toll-like receptor 4 modulates skeletal muscle substrate metabolism. Am J Physiol Endocrinol Metab 298: E988–E998.
17. Furuhashi M. Ura N. Takizawa H. Yoshida D. Moniwa N. Murakami H. et al. (2004) Blockade of the renin–angiotensin system decreases adipocyte size with improvement in insulin sensitivity. J Hypertens 22: 1977–1982.
18. Garrison R. Kannel W. Stokes J. 3rd Castelli W. (1987) Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 16: 235–251.
19. Goossens G. Moors C. van der Zijl N. Venteclef N. Alili R. Jocken J. et al. (2012) Valsartan improves adipose tissue function in humans with impaired glucose metabolism: a randomized placebo-controlled double-blind trial. PloS ONE 7: e39930.
20. Henriksen E. Jacob S. Kinnick T. Teachey M. Krekler M. (2001) Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 38: 884–890.
21. Ichikawa Y. (2007) Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome. Intern Med 46: 1331–1336.
22. Kurtz T. (2005) Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator. Acta Diabetol 42(Suppl. 1): S9–S16.
23. Kurtz T. (2006) New treatment strategies for patients with hypertension and insulin resistance. Am J Med 119: S24–S30.
24. Laakso M. Karjalainen L. Lempiainen-Kuosa P. (1996) Effects of losartan on insulin sensitivity in hypertensive subjects. Hypertension 28: 392–396.
25. Lteif A. Chisholm R. Gilbert K. Considine R. Mather K. (2012) Effects of losartan on whole body, skeletal muscle and vascular insulin responses in obesity / insulin resistance without hypertension. Diabetes Obes Metab 14: 254–261.
26. Moan A. Hoieggen A. Seljeflot I. Risanger T. Arnesen H. Kjeldsen S. (1996) The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. J Hypertens 14: 1093–1097.
27. Moller D. Flier J. (1991) Insulin resistance – mechanisms, syndromes, and implications. N Engl J Med 325: 938–948.
28. Mori Y. Tanaka T. Matsuura K. Yokoyama J. Utsunomiya K. (2011) Influence of telmisartan on insulin response after glucose loading in obese patients with hypertension: ARB Trial of Hypertension in Obese Patients with Hyperinsulinemia Assessed by Oral Glucose Tolerance Test (ATHLETE). Adv Ther 28: 698–706.
29. Nishimura H. Sanaka T. Tanihata Y. Naito T. Higuchi C. Otsuka K. (2008) Losartan elevates the serum high-molecular weight-adiponectin isoform and concurrently improves insulin sensitivity in patients with impaired glucose metabolism. Hypertens Res 31: 1611–1618.
30. Paolisso G. Tagliamonte M. Gambardella A. Manzella D. Gualdiero P. Varricchio G. et al. (1997) Losartan mediated improvement in insulin action is mainly due to an increase in non-oxidative glucose metabolism and blood flow in insulin-resistant hypertensive patients. J Hum Hypertens 11: 307–312.
31. Parhofer K. Birkeland K. Defronzo R. Del Prato S. Bhaumik A. Ptaszynska A. (2010) Irbesartan has no short-term effect on insulin resistance in hypertensive patients with additional cardiometabolic risk factors (i-RESPOND). Int J Clin Pract 64: 160–168.
32. Perlstein T. Henry R. Mather K. Rickels M. Abate N. Grundy S. et al. (2012) Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucose. Clin Sci (Lond) 122: 193–202.
33. Picard F. Auwerx J. (2002) PPAR(gamma) and glucose homeostasis. Annu Rev Nutr 22: 167–197.
34. Prasad A. Quyyumi A. (2004) Renin–angiotensin system and angiotensin receptor blockers in the metabolic syndrome. Circulation 110: 1507–1512.
35. Sasaki K. Kushiro T. Nakagawa S. Kanmatsuse K. (1999) [Effects of angiotensin II receptor antagonist on insulin sensitivity and sympathetic activity in spontaneously hypertensive rats]. Nihon Jinzo Gakkai Shi 41: 692–696.
36. Scheen A. (2004 a) Renin–angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 30: 487–496.
37. Scheen A. (2004 b) Renin–angiotensin system inhibition prevents type 2 diabetes mellitus. Part 2. Overview of physiological and biochemical mechanisms. Diabetes Metab 30: 498–505.
38. Schupp M. Janke J. Clasen R. Unger T. Kintscher U. (2004) Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 109: 2054–2057.
39. Shiuchi T. Iwai M. Li H. Wu L. Min L. Li J. et al. (2004) Angiotensin II type-1 receptor blocker valsartan enhances insulin sensitivity in skeletal muscles of diabetic mice. Hypertension 43: 1003–1010.
40. Shoelson S. Lee J. Goldfine A. (2006) Inflammation and insulin resistance. J Clin Invest 116: 1793–1801.
41. Sloniger J. Saengsirisuwan V. Diehl C. Dokken B. Lailerd N. Lemieux A. et al. (2005) Defective insulin signaling in skeletal muscle of the hypertensive TG(mREN2)27 Rat. Am J Physiol Endocrinol Metab 288: E1074–E1081.
42. van der Zijl N. Moors C. Goossens G. Hermans M. Blaak E. Diamant M. (2011) Valsartan improves {beta}-cell function and insulin sensitivity in subjects with impaired glucose metabolism: a randomized controlled trial. Diabetes Care 34: 845–851.
43. Vitale C. Mercuro G. Castiglioni C. Cornoldi A. Tulli A. Fini M. et al. (2005) Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 4: 6.
44. Wang Y. McPherson K. Marsh T. Gortmaker S. Brown M. (2011) Health and economic burden of the projected obesity trends in the USA and the UK. Lancet 378: 815–825.
45. Wei Y. Sowers J. Clark S. Li W. Ferrario C. Stump C. (2008) Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. Am J Physiol Endocrinol Metab 294: E345–E351.
46. Wei Y. Sowers J. Nistala R. Gong H. Uptergrove G. Clark S. et al. (2006) Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J Biol Chem 281: 35137–35146.